Loading people...
Jorge Conde is a General Partner at Andreessen Horowitz (a16z), where he co-leads the firm's Bio + Health fund. He is a prominent venture capitalist with a background as a co-founder and CEO of a genomics company, focusing on investments at the intersection of biology and technology.
Jorge Conde invests in companies within the biotech and healthcare sectors, specifically those at the convergence of biology and technology. His focus areas include advanced therapeutics, precision diagnostics, digital health solutions, synthetic biology, and computational biology platforms.
Jorge Conde works as a General Partner at Andreessen Horowitz (a16z), a leading venture capital firm. He is based at their offices and plays a key role in their Bio + Health investment initiatives.
Jorge Conde is a General Partner at Andreessen Horowitz in the San Francisco Bay Area, where he co-leads the firm's Bio + Health fund. He helps manage the firm's $1.5 billion Bio + Health Fund IV, directing investments across therapeutics, diagnostics, and computational biology. Prior to joining the venture capital firm in 2017, Conde served as Chief Strategy Officer and Chief Financial Officer at clinical-stage biopharmaceutical company Syros Pharmaceuticals. He also co-founded and acted as Chief Executive Officer of personal genomics startup Knome, and previously worked in biotechnology investment banking at Morgan Stanley. He holds an MBA from Harvard Business School and serves on the boards of healthcare technology companies including Asimov, Komodo Health, and Octant Bio. His career focuses on the intersection of computer science, engineering, and life sciences to advance modern medicine.
Jorge Conde stands as a prominent General Partner at Andreessen Horowitz (a16z), one of the world's leading venture capital firms. At a16z, he plays a pivotal role in co-leading the firm's dedicated Bio + Health fund, a testament to his deep expertise and vision in the life sciences sector. His investment thesis centers on identifying and nurturing companies that are innovating at the crucial intersection of biology and technology. This encompasses a broad spectrum of areas, including advanced therapeutics, precision diagnostics, transformative digital health solutions, synthetic biology, and computational biology platforms.
Before joining Andreessen Horowitz, Jorge Conde established a distinguished career marked by entrepreneurial success and scientific acumen. He was the co-founder and former CEO of Knome, a pioneering genomics company that focused on personal genome interpretation. This hands-on experience as a founder provided him with invaluable insights into the challenges and opportunities faced by early-stage technology companies, particularly within the complex biotech landscape. His leadership at Knome demonstrated his ability to translate complex scientific concepts into viable commercial ventures, a skill he now leverages to identify promising startups for a16z.
Conde's academic background is equally impressive, holding degrees from prestigious institutions such as Harvard University and the Massachusetts Institute of Technology (MIT). This strong foundation in both science and technology underpins his strategic approach to venture capital, enabling him to thoroughly evaluate the scientific merit and market potential of prospective investments. His career trajectory reflects a consistent commitment to advancing human health through technological innovation.
As a General Partner at Andreessen Horowitz, Jorge Conde is instrumental in shaping the future of healthcare and biotechnology. He actively partners with visionary founders, providing not just capital but also strategic guidance, operational support, and access to a vast network. His work at a16z is focused on backing companies that are poised to revolutionize how we understand, treat, and prevent disease, ultimately aiming to improve global health outcomes. His contributions reinforce Andreessen Horowitz's position at the forefront of investing in disruptive technologies across various industries.
